Release time: 2022/12/22 09:00
Last updated: 2022/12/22 09:33
As the environment continues to change, the health threats faced by humans continue to escalate. Yang Zhonghan believes: “While environmental threats are escalating, the healthcare products should also be upgraded.” Using the second-generation small molecule fucoidan extraction technology in addition to the traditional enzyme hydrolysis technology, it is supplemented by high-pressure filtration and porous structure instant technology. Through special patented carrier technology, the physiological regulating function of small molecule fucoidan is completely retained, and the new technology is used to remove the waste and retain the essence to extract high-quality fucoidan. The purity and high functionality of fucoidan, a small molecule molecule, greatly improves the body’s regulating power!
The FOII® second-generation small molecule oligo fucoidan has been successfully developed. In addition to receiving the SNQ national quality symbol “high concentrated” and “double the efficacy” comments, the results of this human clinical trial at the Medical Center and Teaching Hospital are also exciting.
The second-generation small molecule oligo fucoidan is more focused on improving safety and bioactivity. The human clinical trial completed in cooperation with the medical center not only confirms its safety, but also confirms that its function can significantly improve the microenvironment, adjust physical fitness and strengthen acquired adjustment ability.
Since fucoidan is suitable for a wide range of age groups and body types, taking into account the convenience of consumption and consumer demand, the FOII® second-generation small molecule oligo fucoidan is a rare liquid dosage form of Taiwanese small molecule fucoidan in the market. Compared with solid dosage forms, in addition to improving body utilization, the palatability has been measured to be over 95%. It is suitable for multiple consumption methods such as direct drinking and swallowing. Whether it is the elderly or children, it can easily achieve efficient health assistance.
Adhering to the spirit of “medicine research and development”, Translab International Ltd. has established a brand in the field of biomedical development.
“The most basic purpose of health food is to supplement the nutrients we need and to perform functions, so Translab pays special attention to research and development technology updates. We adhere to the spirit of “medicine research and development” and strictly follow scientific evidence to ensure the quality and efficacy of our products.” Translab International Ltd., General Manager Huang Mingxin said this.
In recent years, in addition to entering CDMO (Contract Development and Manufacturing Organization), Translab International Ltd. has also developed steadily and highly recognized in biotechnology and health care with the assistance of scientific research, and will continue to invest more in the future. Human clinical trials have injected new strength into Taiwan’s biotechnology industry.
Learn more: https://reurl.cc/oZXpEj
News website: https://news.tvbs.com.tw/life/1996539
